Research programme: rheumatoid arthritis vaccine - CEL-SCI

Drug Profile

Research programme: rheumatoid arthritis vaccine - CEL-SCI

Alternative Names: CEL-2000; CEL-4000; DerG-PG70 LEAPS - CEL-SCI; Rheumatoid arthritis vaccine - CEL-SCI

Latest Information Update: 24 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CEL-SCI Corporation
  • Class Antirheumatics; Peptides; Vaccines
  • Mechanism of Action CD4 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 21 Feb 2017 Preclinical data in Rheumatoid arthritis released by CEL-SCI Corporation
  • 14 Nov 2016 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis is released by CEL-SCI
  • 04 Nov 2015 Rheumatoid arthritis vaccine accepted for Niche Assessment Programme by the National Institutes of Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top